NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
Biosimilars
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
